Eylea | Aflibercept Injection while Breastfeeding
Most health expert recommend six month of exclusive breastfeeding but statics suggest that numbers are not good, almost 95% mothers start breastfeeding but this number drops to 40% in first three month and further it drops to 15% till fifth month. Sometime its due to need of medication usage. Because of these statics its important to provide good information on safety of drugs in breastfeeding so that it can be improved when possible. In this FAQ sheet we will discuss about exposure to Eylea | Aflibercept Injection while breastfeeding. We will also discuss about common side effects and warnings associated with Eylea | Aflibercept Injection.

What is Eylea | Aflibercept Injection used for?


EYLEA is indicated for the treatment of: EYLEA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) (1.1) Macular Edema Following Retinal Vein Occlusion (RVO) (1.2) Diabetic Macular Edema (DME) (1.3) Diabetic Retinopathy (DR) (1.4) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR)

I am breastfeeding mother and I am using Eylea | Aflibercept Injection. Can it have any bad effect on my kid? Shall I search for better alternative?

Eylea | Aflibercept Injection low risk for breastfeeding
Aflibercept is the one and only active ingredient present in Eylea | Aflibercept Injection. Aflibercept in itself is a low risk drug for lactation so it is easy to understand that Eylea | Aflibercept Injection also comes in category of Low Risk item while breastfeeding. Below is the summary of Aflibercept in breastfeeding.

Eylea | Aflibercept Injection Breastfeeding Analsys


Aflibercept while Breastfeeding

Low Risk

Proteína de fusión recombinante que suprime la neovascularización y disminuye la permeabilidad vascular.Indicada en inyección intravítrea en formas de degeneración y edema maculares y neovascularización coroidea miópica. A fecha de última actualización no encontramos datos publicados sobre su excreción en leche materna. Tras la administración intravítrea las concentraciones plasmáticas a los 1-3 días son bajas (de 0 a 0,05 micorgramos/mL) e indetectables a las 2 semanas. Esa concentración es entre 50 y 500 veces más baja de la necesaria para tener algún efecto sistémico. Además, se une al factor de crecimiento endotelial vascular formando un complejo inerte que, como otras proteínas se degrada por catabolismo protéico. No se acumula tras dosis repetidas cada 4 semanas (EMA 2017). Su elevadísimo peso molecular hacen muy improbable su paso a leche.Por su naturaleza protéica es inactivado en tracto gastrointestinal, no absorbiéndose, por lo que su biodisponibilidad oral es prácticamente nula, salvo en prematuros y periodo neonatal inmediato en los que puede haber mayor permeabilidad intestinal.

Eylea | Aflibercept Injection Breastfeeding Analsys - 2


Aflibercept while Breastfeeding

CAS Number: 862111-32-8

Is Eylea | Aflibercept Injection safe while breastfeeding

This record refers to the use of intravitreal aflibercept for macular degeneration. No information is available on the use of aflibercept during breastfeeding. The manufacturer estimates that after intravitreal administration of 2 mg, the mean maximum plasma concentration of free aflibercept is more than 100-fold lower than the concentration of aflibercept required to half-maximally bind systemic vascular endothelial growth factor. Additionally, aflibercept is a large protein molecule with a molecular weight of 115,000, Therefore, the amount in breastmilk is likely to be clinically unimportant after intravitreal injection. However, the manufacturer recommends avoiding the drug during breastfeeding.


What should I do if already breastfed my kid after using Eylea | Aflibercept Injection?

Eylea | Aflibercept Injection is in the category of low risk, if you have already used it then its not a big deal if health and behavior of baby is good. However your health care provider shall be aware of the fact that you have used Eylea | Aflibercept Injection so you should inform him based on your convenience.


I am nursing mother and my doctor has suggested me to use Eylea | Aflibercept Injection, is it safe?

Eylea | Aflibercept Injection comes in category of low risk and if your doctor is aware that you are breastfeeding it should be ok to use without much concerns.


If I am using Eylea | Aflibercept Injection, will my baby need extra monitoring?

Not much monitoring required while using Eylea | Aflibercept Injection


Who can I talk to if I have questions about usage of Eylea | Aflibercept Injection in breastfeeding?

US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week

Drug Brands with same Active ingredients

Zaltrap | Ziv-aflibercept Solution, Concentrate